Emerging therapies in Parkinson disease — repurposed drugs and new approaches

Emerging therapies in Parkinson disease — repurposed drugs and new approaches

Publication date: Mar 12, 2019

Parkinson disease (PD) treatment options have conventionally focused on dopamine replacement and provision of symptomatic relief. Current treatments cause undesirable adverse effects, and a large unmet clinical need remains for treatments that offer disease modification and that address symptoms resistant to levodopa. Advances in high-throughput drug screening methods for small molecules, developments in disease modelling and improvements in analytical technologies have collectively contributed to the emergence of novel compounds, repurposed drugs and new technologies. In this Review, we focus on disease-modifying and symptomatic therapies under development for PD. We review cellular therapies and repurposed drugs, such as nilotinib, inosine, isradipine, iron chelators and anti-inflammatories, and discuss how their success in preclinical models has paved the way for clinical trials. We provide an update on immunotherapies and vaccines. In addition, we review non-pharmacological interventions targeting motor symptoms, including gene therapy, adaptive deep brain stimulation (DBS) and optogenetically inspired DBS. Given the many clinical phenotypes of PD, individualization of therapy and precision of treatment are likely to become important in the future.

Elkouzi, Ahmad, Vedam-Mai, Vinata, Eisinger, Robert S.., and Okun, Michael S.. Emerging therapies in Parkinson disease – repurposed drugs and new approaches. 20106. 2019 Nature Reviews Neurology.

Concepts Keywords
Chelators Drug screening
Clinical Trials Virotherapy
DBS Parkinson’s disease
Deep Brain Stimulation Immunotherapy
Dopamine Immunotherapies
Immunotherapies Deep brain stimulation
Inosine
Iron
Levodopa
Nature
Neurology
Nilotinib
Parkinson
Pharmacological
Phenotypes
Throughput

Semantics

Type Source Name
gene UNIPROT LRP2
gene UNIPROT MCF2L
drug DRUGBANK Spinosad
drug DRUGBANK Iron
drug DRUGBANK Isradipine
drug DRUGBANK Inosine
drug DRUGBANK Nilotinib
disease MESH development
drug DRUGBANK Levodopa
gene UNIPROT LARGE1
drug DRUGBANK Dopamine
disease DOID Parkinson disease
disease MESH Parkinson disease

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *